Astrazeneca Plc $AZN Shares Sold by Brandywine Oak Private Wealth LLC

Brandywine Oak Private Wealth LLC cut its stake in Astrazeneca Plc (NYSE:AZN) by 52.9% in the first quarter, HoldingsChannel reports. The institutional investor owned 28,812 shares of the company’s stock after selling 32,357 shares during the quarter. Brandywine Oak Private Wealth LLC’s holdings in Astrazeneca were worth $5,682,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Triumph Capital Management acquired a new stake in Astrazeneca during the 3rd quarter valued at $25,000. MV Capital Management Inc. purchased a new stake in Astrazeneca in the 4th quarter valued at about $26,000. Bangor Savings Bank grew its holdings in Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after purchasing an additional 154 shares during the period. Eagle Bay Advisors LLC purchased a new stake in shares of Astrazeneca during the 4th quarter valued at $30,000. Finally, YANKCOM Partnership purchased a new stake in Astrazeneca during the fourth quarter valued at about $31,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AZN has been the subject of several recent research reports. Barclays reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Astrazeneca in a research report on Monday, June 8th. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Astrazeneca currently has an average rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Stock Performance

Shares of AZN opened at $181.01 on Wednesday. The stock has a market capitalization of $280.73 billion, a P/E ratio of 27.18, a P/E/G ratio of 1.53 and a beta of 0.25. Astrazeneca Plc has a 12-month low of $137.23 and a 12-month high of $212.71. The firm’s 50 day moving average is $185.64 and its 200-day moving average is $186.60. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Equities research analysts anticipate that Astrazeneca Plc will post 9.39 EPS for the current fiscal year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.